---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-23-038757"
form_type: "8-K"
ticker: "RCUS"
cik: "0001724521"
company_name: "Arcus Biosciences, Inc."
filed_at: "2023-08-07T23:59:59+00:00"
generated_at: "2026-06-12T04:31:58.781311+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Arcus Q2 net loss $75M, cash $1.0B; deprioritizes etrumadenant in mCRPC

## Summary
- Cash $1.0B vs $1.1B at Dec 2022; 2023 cash burn guided $290-325M; funding into 2026.
- Q2 net loss $75M vs $67M YoY; revenue $29M vs $27M; R&D expenses $84M vs $70M.
- Domvanalimab ARC-7 data: 33% PFS risk reduction for doublet vs PD-1 monotherapy at ~18-mo follow-up.
- Etrumadenant in mCRPC deprioritized; ARC-6 analysis shows insufficient clinical benefit to warrant further investment.
- Gilead collaboration expanded to inflammation; Arcus gets $35M upfront; Gilead bought 1M shares at $19.26, raising stake to 19.9%.

## SEC filing metadata
- accession: 0000950170-23-038757
- form_type: 8-K
- ticker: RCUS
- cik: 0001724521
- company_name: Arcus Biosciences, Inc.
- filed_at: 2023-08-07T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1724521/000095017023038757/0000950170-23-038757-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1724521/000095017023038757/rcus-20230807.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-23-038757
- JSON: https://secwatch.observer/filing/0000950170-23-038757.json
- Plain text: https://secwatch.observer/filing/0000950170-23-038757.txt

## Key facts
- Earnings Releases
  Arcus Biosciences, Inc. reported financial results for the second quarter ended June 30, 2023.
  - Period: the second quarter ended June 30, 2023
  - Result: reported results
  source text: Arcus Biosciences, Inc. issued a press release announcing its financial results for the three and six months ended June 30, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1724521/000095017023038757/0000950170-23-038757-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.